Compound Information | SONAR Target prediction |
Name: | TENIPOSIDE |
Unique Identifier: | SPE01504094 |
MolClass: | Checkout models in ver1.5 and ver1.0 |
Molecular Formula: | |
Molecular Weight: | 624.401 g/mol |
X log p: | 16.146 (online calculus) |
Lipinksi Failures | 2 |
TPSA | 125.44 |
Hydrogen Bond Donor Count: | 0 |
Hydrogen Bond Acceptors Count: | 13 |
Rotatable Bond Count: | 6 |
Canonical Smiles: | COc1cc(cc(OC)c1O)C1C2C(COC2=O)C(OC2OC3COC(OC3C(O)C2O)c2sccc2)c2cc3OCOc 3cc12 |
Source: | semisynthetic |
Therapeutics: | antineoplastic |
Generic_name: | Teniposide |
Drug_type: | Approved Drug |
Kegg_compound_id: | C11153 |
Drugbank_id: | APRD00649 |
Logp: | 1.963 |
Cas_registry_number: | 29767-20-2 |
Drug_category: | Antineoplastic Agents; ATC:L01CB02 |
Indication: | Treatment of refractory acute lymphoblastic leukaemia |
Pharmacology: | Teniposide is a phase-specific cytotoxic drug, acting in the late S or early G 2 phase of the cell cycle, thus preventing cells from entering mitosis. Teniposide causes dose-dependent single- and double-stranded breaks in DNA and DNA: protein cross-links. The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA. |
Mechanism_of_action: | Binds to and inhibits DNA topoisomerase II. The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which are a reflection of the stabilization of a topoisomerase II-DNA intermediate. |
Organisms_affected: | Humans and other mammals |